Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43728 | 1.00 | HPGD (0.62) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL42958 | 1.00 | HPGD (0.62) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| Hydrazine SCHEMBL28122436 | 0.97 | HPGD (0.59) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL27963722 | 0.91 | HPGD (0.65) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL40057 | 0.90 | MEN1 (0.64) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL40056 | 0.90 | MEN1 (0.64) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL181768 | 0.90 | MEN1 (0.64) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL18275033 | 0.89 | HPGD (0.53) | HPGDHSD17B10RECQLKMT2AMEN1 | |
| SCHEMBL43357 | 0.89 | HPGD (0.66) | HPGDHSD17B10RECQLKMT2AMAPT | |
| SCHEMBL1439980 | 0.89 | HPGD (0.61) | HPGDHSD17B10RECQLKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747261-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | Accutar Biotechnology Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| CN-119528901-B | Thiazole compound, dessumo and/or deubiquitinase inhibitor, and preparation methods and applications thereof | Shanghai tongji hospital (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2026102632-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | HANSONSBECK INDUSTRIES LIMITED (CN) | 2026-05-21 | — | — | WO | disclosed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | ACERTA PHARMA B.V. (NL) | 2026-05-05 | — | — | US | disclosed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006110884-A2 | 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006040192-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| EP-0445796-B1 | Derivatives of acetic acid containing peptide bonds | HOFFMANN LA ROCHE (CH) | 1998-06-17 | — | — | EP | disclosed |
| US-5430024-A | Peptides bearing N-terminal amidino moieties and their use as inhibitors of platelet aggregation | HOFFMANN-LA ROCHE INC. (US) | 1995-07-04 | — | — | US | disclosed |
| US-5273982-A | An amidinoaryleneamidoalkylpiperazinyleneacetic acid | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0445796-A2 | Derivatives of acetic acid | F. HOFFMANN-LA ROCHE AG (CH) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 1203/4885HSD17B10 421/4885RECQL 1812/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | HPGD 376/4885HSD17B10 65/4885RECQL 926/4885 |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | HPGD 515/4885HSD17B10 1821/4885RECQL 95/4885 |
| US-12616682-B2 | 1-H-pyrrolo[2,3-c]pyridine compounds | MEN1, PKD1, PKD2 | HPGD 2427/4885HSD17B10 3811/4885RECQL 2122/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | HPGD 2925/4885HSD17B10 1319/4885RECQL 4498/4885 |
| US-12637458-B2 | Imidazo[1,2-a]pyridine compounds and their use in therapy | OGFR, CBR3, CBR1 | HPGD 2803/4885HSD17B10 2865/4885RECQL 2612/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | HPGD 707/4885HSD17B10 141/4885RECQL 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.